<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538040</url>
  </required_header>
  <id_info>
    <org_study_id>BETD-001</org_study_id>
    <nct_id>NCT04538040</nct_id>
  </id_info>
  <brief_title>Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine</brief_title>
  <official_title>An Open Label Study Evaluating the Safety and Efficacy of Switching From Rilpivirine/Emtricitabine/Tenofovir Alafenamide in Combination With Dolutegravir, to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Combination With Doravirine, in Male HIV+ Subjects &gt; 45 Years With Multi-drug Resistant Virus and Virologic Suppression (Documented With at Least One Viral Load Result &lt; 50 Copies Per mL) During the Last 6 Months on Current Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quest Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Quest Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study proposal is an open label observational trial for maintenance of virologic&#xD;
      suppression, and is designed as a non- inferiority switch trial. The study will involve&#xD;
      approximately 30 patients, which includes a PK arm of approximately 10 patients. The study&#xD;
      will also include secondary outcomes of quality of life (QOL) and weight changes&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Patients with prior NUC or NNRTI resistance (but not to rilpivirine or doravirine) will&#xD;
      maintain their virologic suppression after a drug regimen switch from&#xD;
      rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to&#xD;
      bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine. The switch&#xD;
      therapy will avoid food interactions, and will be well tolerated by subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">April 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 21, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Suppression</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Percentage of patients with viral HIV load (VL) &lt;50 and &lt;200 copies/mL at 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of study drug</measure>
    <time_frame>Week 48</time_frame>
    <description>Tolerability of study drugs will be assessed by summarizing the number of AE/SAEs occurring during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>Week 48</time_frame>
    <description>Assess changes in BMI due to treatment switch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity</measure>
    <time_frame>Week 48</time_frame>
    <description>Improvement in work productivity and activity as measured by Work Productivity and Activity Impairment Questionnaire (WPAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Assessment</measure>
    <time_frame>Week 4 (+/- 14 days) with time points at predose (-0.5 hr), 0.5, 1, 2, 4, 6, 8, 12, and 24 hours</time_frame>
    <description>Subject plasma concentration-time data of bictegravir and doravirine will be analyzed using non-compartmental model (WinNonlinÂ®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Assessment</measure>
    <time_frame>Day 28, Weeks 12, 24, 36, &amp; 48</time_frame>
    <description>Assess AE's of any grade and relationship to the drug combination occurring in at least 5% of participants or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wellbeing Improvement</measure>
    <time_frame>Week 48</time_frame>
    <description>Improvement in well-being and sleep inventory as measured by The Pittsburgh Sleep Quality Index (PSQI). Minimum score is 0 and maximum score is 21. A higher score indicates worse quality sleep.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Biktarvy + Doravirine Switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets + doravirine 100mg tablets taken orally once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch</intervention_name>
    <description>Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.</description>
    <arm_group_label>Biktarvy + Doravirine Switch</arm_group_label>
    <other_name>Biktarvy + Pifeltro Switch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV positive Males, age 45 or older&#xD;
&#xD;
          -  Any genotypic or phenotypic resistance except k65R, 69 insertion, integrase&#xD;
             resistance, or resistance to rilpivarine or doravirine.&#xD;
&#xD;
          -  Receiving combination antiretroviral regimen of rilpivirine/emtricitabine/tenofovir&#xD;
             alafenamide in combination with dolutegravir &gt; 12 months and with viral load &lt;50&#xD;
             copies/ mL on at least one occasion within the six months prior to switch.&#xD;
&#xD;
          -  Suppressed viral load as defined by one plasma HIV RNA level &lt; 50 copies/mL within&#xD;
             previous 6 months.&#xD;
&#xD;
          -  Capable of providing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any current or prior integrase inhibitor resistance&#xD;
&#xD;
          -  Nucleoside reverse transcriptase (NRTI) mutation 69 insertion or k65R mutation&#xD;
&#xD;
          -  Documented second generation non-nucleoside reverse transcriptase inhibitor (NNRTI)&#xD;
             resistance (rilpivirine or doravirine)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SFOMG Private Practice</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multi-drug resistant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

